The Lead Episode 156: A Discussion of The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial-The Lead Episode 156 Bonus Video File

Video Transcription

Video Summary

This episode of <em>The LEAD</em> discusses a sub-study of the SHAM-PVI trial, asking whether improvements in quality of life after atrial fibrillation (AF) ablation are truly linked to reductions in AF burden or partly due to placebo. In 126 patients randomized to cryoballoon ablation or a sham procedure, lower AF burden was strongly associated with better quality-of-life scores, regardless of treatment group. Symptoms most tied to AF burden included palpitations, dyspnea, fatigue, exercise intolerance, and weakness.

The guests agreed AF ablation improves symptoms, but differed on whether this study proves there is no placebo effect. They emphasized that the findings support AF burden as clinically meaningful, yet do not fully exclude placebo influence.

In practice, they highlighted a growing focus on AF burden, especially with digital monitoring, and said anticoagulation decisions should be individualized using AF burden, stroke risk, comorbidities, and patient preferences rather than burden alone.

Keywords

atrial fibrillation ablation

AF burden

quality of life

placebo effect

cryoballoon ablation